Wataru Fukuokaya

Development and Validation of the JIKEI‐YAYOI Score for Predicting Castration Resistance in Metastatic Castration‐Sensitive Prostate Cancer Treated With ARSI‐Based Doublet Therapy

Metastatic castration‐sensitive prostate cancer (mCSPC) is a heterogeneous disease with variable clinical outcomes despite advances in androgen receptor signaling inhibitor (ARSI)‐based therapy. We aimed to develop and externally validate a prognostic model for predicting progression to castration‐resistant prostate ca...

Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio and Clinicopathological Factors in a Multicenter Cohort of Urothelial Carcinoma Treated with Adjuvant Nivolumab.

Prognostic Stratification in High‐Volume Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line Androgen Receptor Pathway Inhibitor–Based Combination Therapy

We aimed to stratify clinical risk among patients with high‐volume metastatic hormone‐sensitive prostate cancer (mHSPC) treated with first‐line androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT).

Machine learning integrated explainable artificial intelligence in predicting toxicities of enfortumab vedotin in urothelial carcinoma: an exploratory study.

Preliminary, hypothesis-generating findings suggest ML may predict EV-related toxicities, but single train-test split, small event counts, and lack of external validation preclude clinical use.